Behavior is one of the most informative functional readouts in translational research. Whether evaluating neurological disorders, chronic pain, pruritus, autoimmune diseases, or gene therapies, behavioral changes often provide the earliest evidence of therapeutic efficacy. However, generating reliable behavioral data in non-human primate (NHP) studies has traditionally depended on labor-intensive video review and subjective human observation, creating challenges in consistency, scalability, and regulatory reproducibility.
At Prisys Biotech, we are transforming this process through an AI-powered behavioral phenotyping platform that combines multi-camera 3D computer vision, markerless motion capture, behavioral classification, and digital biomarker development. Rather than simply recording animal behavior, the platform converts complex movements into quantitative, objective, and traceable datasets that can be integrated into modern preclinical drug development.
Why Conventional Behavioral Assessment Is No Longer Enough
Behavioral endpoints remain essential across numerous therapeutic areas because they directly reflect functional outcomes that cannot always be captured by molecular biomarkers or imaging alone. In studies involving Parkinson's disease, Alzheimer's disease, stroke, chronic pain, atopic dermatitis, or neuropsychiatric disorders, subtle behavioral improvements frequently represent meaningful evidence of pharmacological activity.
Despite their importance, conventional behavioral assessments present several limitations. Long-term NHP studies often generate hundreds of hours of video recordings that require manual review by experienced observers. Different evaluators may apply slightly different scoring criteria, while fatigue and subjective interpretation inevitably introduce variability. More importantly, manual scoring provides only summarized observations rather than continuous, frame-level behavioral information, making it difficult to capture subtle treatment effects or establish fully traceable datasets for regulatory submissions.
As preclinical drug development increasingly relies on objective and reproducible evidence, AI-assisted behavioral analysis has emerged as a powerful solution to overcome these challenges.
Building a Digital Phenotyping Platform for Non-Human Primates
At Prisys, our NHP behavioral analysis platform extends beyond conventional video analysis software. It represents a comprehensive digital phenotyping ecosystem designed specifically for translational research.
The platform integrates synchronized multi-camera imaging, three-dimensional markerless pose estimation, AI-driven behavioral recognition, behavioral database construction, and translational analytics into a unified workflow. This approach enables researchers to continuously monitor spontaneous behaviors while automatically generating standardized quantitative endpoints across individual animals and entire studies.
Over time, the platform also supports the development of disease-specific behavioral databases, allowing researchers to compare normal behavioral baselines with disease progression and therapeutic responses. Rather than analyzing isolated experiments, the system continuously accumulates digital behavioral assets that enhance future model development and translational research.
Markerless 3D Motion Capture Enables Natural Behavioral Observation
Traditional motion capture systems typically require reflective markers attached to the subject, an approach that is impractical for long-term studies in non-human primates and may interfere with natural movement.
Prisys instead utilizes synchronized multi-view computer vision to reconstruct three-dimensional skeletal movements without physical markers. The AI automatically identifies anatomical landmarks, including the head, limbs, trunk, and joints, allowing precise reconstruction of body posture and locomotion within standard housing environments.
Because multiple synchronized cameras observe the animal simultaneously, the system substantially reduces occlusion problems commonly encountered with conventional two-dimensional video recordings. Animals can therefore be monitored continuously without restraint, anesthesia, or behavioral interference.
From Movement Tracking to Digital Behavioral Biomarkers
Capturing movement represents only the first step. The true value of AI lies in transforming motion data into biologically meaningful behavioral endpoints.
Our behavioral analysis platform automatically classifies a wide spectrum of behaviors, including locomotion, climbing, grooming, scratching, resting, posture transitions, hand movements, and gait characteristics. Rather than simply counting behavioral events, the system measures behavioral frequency, duration, spatial trajectories, joint kinematics, movement velocity, acceleration, and limb coordination.
These quantitative parameters provide highly sensitive digital biomarkers capable of detecting subtle pharmacodynamic responses that may precede observable clinical improvements. Such objective measurements are particularly valuable in neurological diseases where small functional changes often represent early therapeutic benefits.
AI Improves Objectivity and Scalability
One of the greatest advantages of AI-based behavioral analysis is the ability to replace subjective observation with standardized computational evaluation.
Instead of relying on manual video review, the platform processes continuous recordings automatically and applies identical analytical criteria across every animal within a study. This eliminates inter-observer variability while enabling frame-by-frame behavioral tracking throughout the entire experimental period.
Every behavioral event remains linked to the original video record, creating a fully traceable analytical workflow that supports quality assurance, data verification, and regulatory documentation. As drug developers increasingly seek reproducible digital endpoints, this level of transparency represents a significant advantage over conventional behavioral scoring.
Expanding Behavioral Analysis Beyond Whole-Body Motion
Behavioral phenotyping extends beyond locomotion alone. Facial expressions often provide important indicators of pain, discomfort, and neurological status.
To address this need, Prisys is also developing an advanced three-dimensional facial expression analysis framework based on the Non-Human Primate 3D Grimace Scale (3DGS). By integrating multi-view facial imaging with AI-based feature extraction, this technology enables objective quantification of subtle facial muscle movements that are difficult to assess consistently using conventional visual scoring.
The resulting digital pain biomarkers have broad applications in analgesic drug development, postoperative pain assessment, inflammatory disease models, and animal welfare monitoring.
Applications Across Multiple Therapeutic Areas
Because behavioral endpoints are widely used throughout drug development, AI-powered behavioral phenotyping supports numerous research programs beyond neuroscience.
In central nervous system studies, digital behavioral analysis provides objective evaluation of motor recovery, gait abnormalities, posture, cognition, and functional improvement. Pain research benefits from quantitative assessment of spontaneous movement, avoidance behavior, and facial pain indicators. Dermatology and immunology programs can monitor scratching behavior as a sensitive pharmacodynamic endpoint for chronic pruritus and atopic dermatitis. Gene therapies, cell therapies, and biologics similarly benefit from continuous long-term monitoring of functional recovery that complements molecular and imaging biomarkers.
The Future of Translational Behavioral Science
Preclinical drug development is rapidly moving toward integrated digital phenotyping, where behavioral data are analyzed alongside neuroimaging, electrophysiology, pharmacokinetics, pharmacodynamics, and molecular biomarkers.
At Prisys Biotech, we believe AI-powered behavioral analysis will become an essential component of translational research rather than an optional analytical tool. By combining advanced computer vision with our established non-human primate disease models, clinical imaging capabilities, wireless EEG technologies, and translational neuroscience expertise, we aim to provide drug developers with objective, reproducible, and clinically relevant functional endpoints that improve confidence in preclinical decision-making.
Conclusion
Reliable behavioral assessment remains fundamental to understanding therapeutic efficacy in non-human primate studies. However, modern drug development demands more than subjective observations-it requires quantitative, reproducible, and regulatory-ready evidence.
Through AI-powered 3D markerless motion capture, digital phenotyping, automated behavioral classification, and quantitative biomarker development, Prisys Biotech is helping transform behavioral research from manual observation into a standardized digital science. As the adoption of AI continues to accelerate across preclinical research, digital behavioral analysis will play an increasingly important role in improving translational predictability and supporting the development of safer and more effective therapies.
